Boiron is gaining ground on the Paris stock exchange this Thursday after announcing the appointment of Pascal Houdayer, a former Henkel and Procter & Gamble executive, to the position of CEO.
He will replace Thierry Boiron, who will nevertheless remain at his side as Deputy CEO to carry out specific missions, effective January 1, 2025.
Prior to joining Laboratoires Boiron, Pascal was CEO of Orveon Global (Laura Mercier, bareMinerals, BUXOM) and CEO of NAOS (Bioderma, Institut Esthederm, Etat Pur).
He also worked for German FMCG giant Henkel as Managing Director of the Henkel Beauty Care division and member of the Board of Directors.
The new CEO also spent 19 years with Procter & Gamble in various management positions in France, Switzerland, the USA and Morocco.
Pascal Houdayer will report directly to the company's Board of Directors, of which he will become a member as of January 1, 2025.
This announcement comes at a time when the company announced last month that it would be stepping up its reorganization with the elimination of a further 145 positions in the wake of the delisting of homeopathic medicines in France.
Although the share price rose by 1.7% on Thursday following the announcement of the arrival of a new CEO, it is still down around 33% for the year as a whole.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (44.8%), Europe (25.3%), North America (25.9%) and other (4%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
